Number of pages: 100 | Report Format: PDF | Published date: May 26, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
Report Attribute |
Details |
CAGR |
7.2% |
Base Year for Estimation |
2022 |
Forecast Period |
2023 to 2031 |
Historical Year |
2021 |
Segments Covered |
Test type, Technique Type, Sample Type, and Region |
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global retrovirus testing market is expected to grow at a revenue CAGR of 7.2% from 2023 to 2031.
Retrovirus Testing Market Fundamentals
Retrovirus testing refers to the process of examining a person's blood or other bodily fluids to identify the presence of retroviruses or specific markers associated with retroviral infections. Retroviruses are RNA viruses that can convert their RNA into DNA and integrate it into the host cell's genome. This testing is typically performed to diagnose retroviral infections, monitor the progression of the disease, and assess the effectiveness of treatment. The specific testing method depends on the retrovirus being targeted and the test's purpose.
Retrovirus Testing Market Dynamics
Retroviral infections, such as HIV, continue to pose a substantial global health challenge. Given the widespread occurrence of these infections, there is a growing need for efficient testing methodologies to enable early detection, ongoing monitoring, and effective treatment. Consequently, this drives the retrovirus testing market demand. According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), 4000 individuals, including 1100 young people (15 to 24 years old), contract HIV daily. If current trends continue, 1.2 million additional HIV infections will occur by 2025. In 2021, 650,000 people died of AIDS-related causes, which is one every minute. The increasing awareness about retroviral infections, their modes of transmission, and the importance of early detection has led to the implementation of screening programs. These programs aim to identify infected individuals, prevent transmission, and provide appropriate care.
Consequently, the demand for retrovirus testing has increased. The retrovirus testing market outlook is positive as continuous advancements in diagnostic technologies have improved retrovirus testing accuracy, sensitivity, and speed. Developing nucleic acid amplification techniques, such as PCR, has significantly enhanced the detection capabilities, enabling early diagnosis and monitoring of retroviral infections. Efforts to improve access to healthcare services, particularly in resource-limited settings, have contributed to the expansion of retrovirus testing. Governments and public health agencies across the globe have implemented initiatives to combat retroviral infections. These initiatives involve funding research and development, supporting screening programs, and implementing early diagnosis and treatment policies. There is a growing retrovirus testing industry trend towards point-of-care testing for retrovirus infections. Point-of-care testing allows for rapid and decentralized testing, enabling immediate diagnosis and treatment decisions. The development of compact and portable testing devices, along with advancements in testing technologies, has facilitated the growth of retrovirus testing beyond traditional laboratory settings.
However, retrovirus testing, especially advanced molecular and nucleic acid-based techniques, is expensive. The costs associated with equipment, reagents, laboratory infrastructure, and skilled personnel pose a barrier to widespread adoption, restricting the growth of the retrovirus testing market. Retroviral infections, such as HIV, are still associated with stigma and discrimination in many parts of the world. Fear of social repercussions and discrimination can discourage individuals from seeking testing and healthcare services, which is also cramping the retrovirus testing market growth.
Retrovirus Testing Market Ecosystem
The global retrovirus testing market is analyzed from four perspectives: test type, technique type, sample type, and region.
Retrovirus Testing Market by Test Type
Based on the test types, the global retrovirus testing market is segmented into antibody tests, antigen/antibody tests, nucleic acid tests (NAT), and others.
The antibody tests segment accounted for the largest revenue share of the retrovirus testing market in 2022. Antibody testing has been a well-established and widely used method for retrovirus testing, particularly for infections like HIV. The methodology and protocols for antibody testing have been refined and standardized over the years, gaining trust and acceptance from healthcare professionals and regulatory bodies. In the U.S., 1,736,850 CDC-funded HIV tests were conducted in 2021. Antibody testing is primarily used for screening and diagnosing retroviral infections. It plays a crucial role in identifying individuals who may be infected with the retrovirus, enabling early intervention and appropriate medical care. Antibody testing is generally more cost-effective than other testing methods, such as nucleic acid tests (NATs). The availability of affordable antibody testing kits, including rapid diagnostic tests (RDTs), has contributed to its widespread adoption, especially in resource-limited settings where cost considerations are significant. Antibody testing can be performed in various healthcare settings, ranging from centralized laboratories to point-of-care facilities. It offers scalability and accessibility, allowing for testing to be conducted in diverse healthcare settings, including remote and underserved areas.
The nucleic acid tests (NAT) segment is anticipated to register a lucrative growth rate during the forecasting period from 2023 to 2031. NAT offers high sensitivity and specificity in detecting viral genetic material, making it an effective method for diagnosing retroviral infections. It can detect very low levels of viral particles in the bloodstream, enabling early detection even before the onset of symptoms. Over the years, there has been an increased emphasis on the importance of early detection and screening for retroviral infections. Public health campaigns, education initiatives, and advancements in medical technology have contributed to greater awareness among healthcare professionals and the general population. This has led to an increase in the number of people opting for retrovirus testing, which includes NAT. Technological advancements have made NAT more accessible and efficient. There have been improvements in the sensitivity and speed of NAT assays and the automation of testing processes. These advancements have increased the adoption of NAT by healthcare facilities and laboratories, leading to its rapid growth in the retrovirus testing market. NAT has received regulatory approvals and endorsements from organizations like the U.S. FDA and the WHO. These approvals and guidelines have provided a strong framework for using NAT in retrovirus testing, instilling confidence in healthcare providers and encouraging widespread adoption.
Retrovirus Testing Market by Technique Type
Based on the technique types, the global retrovirus testing market is segmented into high-throughput screening, enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), and others.
The PCR segment accounted for a significant retrovirus testing market share in 2022. PCR is known for its high sensitivity and specificity in detecting retroviral genetic material, such as RNA or DNA. It can amplify and detect even small amounts of viral nucleic acids, making it an effective method for diagnosing retroviral infections. PCR is a well-established and widely used technology in molecular diagnostics. It has been extensively studied, refined, and standardized over the years, making it a trusted method for retrovirus testing. PCR has a broad range of applications in retrovirus testing. It can be used for various purposes, including diagnosis, viral load monitoring, genotyping, and drug resistance testing. Its versatility and adaptability to different testing needs make it a preferred choice for healthcare providers. Numerous commercial PCR kits specifically designed for retrovirus testing are available in the market. These kits provide standardized protocols, reagents, and controls, simplifying testing and ensuring consistent and reliable results. The availability and accessibility of these kits have contributed to the widespread adoption of PCR in the retrovirus testing market.
Retrovirus Testing Market by Sample Type
Based on the Sample Types, the global retrovirus testing market is segmented into blood, serum, body fluids, and others.
The blood segment accounted for the highest revenue share of the retrovirus testing market. Many retroviruses, including HIV and hepatitis C virus (HCV), are primarily transmitted through blood contact. This makes blood testing a crucial method for diagnosing these infections. Blood-based tests directly detect viral particles or antibodies in the bloodstream, providing a reliable indicator of infection. Blood-based retrovirus testing is an integral part of various screening programs implemented by healthcare organizations and public health agencies. These programs aim to identify individuals who may be infected with retroviruses but are asymptomatic. Blood-based retrovirus testing methods, including enzyme immunoassays (EIAs), nucleic acid tests (NATs), and PCR (polymerase chain reaction), have been developed and optimized to ensure high diagnostic accuracy. These tests can detect viral particles or specific antibodies in the blood, providing reliable results for diagnosing and monitoring retroviral infections. Blood testing infrastructure, such as laboratories with the necessary equipment and trained personnel, is often readily available in healthcare settings. This accessibility makes blood-based testing a convenient and widely accessible option for retrovirus diagnosis.
Retrovirus Testing Market by Region
Geographically, the global retrovirus testing market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
The North America region has the largest retrovirus testing market size in terms of revenue generation accounting for around 38.3% share of the market. North America, particularly the United States, has a significant burden of retroviral infections, such as HIV and hepatitis C virus (HCV). The high prevalence of these infections creates a strong demand for retrovirus testing in the region. According to the CDC, around 1.2 million people in the U.S. had HIV at the end of 2021. There has been an increased emphasis on raising awareness about retroviral infections and promoting regular screening in North America. Public health campaigns, education initiatives, and advocacy efforts have increased awareness among healthcare professionals and the general population, increasing demand for retrovirus testing. Governments in North America, including federal, state, and provincial authorities, have implemented various programs and initiatives to combat retroviral infections. These initiatives focus on preventing, diagnosing, and treating retrovirus infections, leading to increased testing rates and demand for retrovirus testing. North America is known for its advancements in medical technology and diagnostics. The region has been at the forefront of developing and adopting innovative retrovirus testing technologies, such as nucleic acid tests (NATs) and point-of-care testing (POCT) devices. These advancements have improved the accuracy, efficiency, and accessibility of retrovirus testing, driving market growth.
Retrovirus Testing Market Competitive Landscape
The prominent players operating in the global retrovirus testingmarket are:
Retrovirus Testing Market Strategic Developments
Retrovirus testing refers to the process of examining a person's blood or other bodily fluids to identify the presence of retroviruses or specific markers associated with retroviral infections.
Asia Pacific can be considered the key growth region due to the surge in retrovirus testing industry trends in China, Japan, and the Indian subcontinent.
The major players operating in the global retrovirus testing market are F. Hoffmann-La Roche Ltd., DiaSorin S.p. A, bioMérieux SA, BD (Becton, Dickinson and Company), and Abbott Laboratories.
The global retrovirus testing market growth is estimated to grow at a revenue CAGR of 7.7% during the forecast period from 2023 to 2031.
The antibody testing segment dominated the retrovirus testing market.
*Insights on financial performance are subject to the availability of information in the public domain